Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Dec
20
2014
Myriad's Breast Cancer Test Patents Not Patent Eligible Honigman Miller Schwartz and Cohn LLP
Jan
29
2015
Supreme Court Holds Claim Construction Facts Are Subject to Clear Error Review Honigman Miller Schwartz and Cohn LLP
May
19
2022
Expert Witness Case Complexity & Vetting – Episode 36 [Podcast] IMS Legal Strategies
Aug
26
2015
Trademarking: Capri Sun Says “Respect the Pouch” IMS Legal Strategies
Dec
1
2022
Chemical Engineering Trends, Intellectual Property Litigation, & Industry Predictions – Episode 50 [PODCAST] IMS Legal Strategies
Oct
19
2016
Monopoly on Medical Marijuana? IMS Legal Strategies
Dec
4
2014
Court-Appointed Experts: The Future of Litigation? IMS Legal Strategies
Oct
7
2015
Dunkin’ Donuts: Your Munchkin Is Showing IMS Legal Strategies
Dec
21
2017
Compounders Who Skirt The FDA: Who Is The Expert Here? IMS Legal Strategies
Jun
25
2019
Episode 2: The Future of STEM and Aerospace Engineering [Podcast] IMS Legal Strategies
Aug
14
2015
U.S. v. Bayer Is Proof ─ Daubert Is Not Hard To Digest IMS Legal Strategies
Mar
17
2017
Are Biosimilars Really That Similar? The $40B Question IMS Legal Strategies
Dec
30
2015
Getting Past Gatekeeper: “No Shoes, No Shirt, No Service” re: Admissibility of Expert Opinions IMS Legal Strategies
Sep
4
2015
Wine Seller Victory in Illinois Qui Tam Lawsuit Horwood Marcus & Berk Chartered
Oct
1
2018
FDA Seeks Civil Monetary Penalties Measures to Enforce Compliance with ClinicalTrials.org Requirements Epstein Becker & Green, P.C.
Oct
29
2018
CMS Seeks to Revamp Medicare Part B Drug Reimbursement through Proposed International Pricing Index (IPI) Model Epstein Becker & Green, P.C.
Aug
11
2022
Impact of COVID-19 on Pharmacist Scope of Practice: Before and After the PREP Act – Diagnosing Health Care [Podcast] Epstein Becker & Green, P.C.
Jul
24
2019
New Jersey’s Highest Court to Decide Whether Employers Are Required to Accommodate Medical Marijuana Use Epstein Becker & Green, P.C.
Aug
12
2019
Legislative Efforts to Curb Sexual Harassment in the Hospitality Industry Finally Reach Fruition in Illinois Epstein Becker & Green, P.C.
Jul
24
2015
FDA Leverages Patient-Reported Information to Monitor Drug Safety Epstein Becker & Green, P.C.
Mar
7
2023
Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023 Epstein Becker & Green, P.C.
May
2
2023
Unpacking Averages: Success Rates for FDA FOIAs by Topic and Requester Epstein Becker & Green, P.C.
Jan
21
2016
No Duty to Accommodate Medical Marijuana Use in New Mexico Epstein Becker & Green, P.C.
May
26
2016
The Scope of FDA’s Proposed Revisions to the IND Regulations May Not Be Sufficient to Achieve Its Stated Goals Epstein Becker & Green, P.C.
Sep
5
2023
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? Epstein Becker & Green, P.C.
Aug
26
2016
New FDA Draft Guidance Shows Limited Compromise with Brand and Generic Drug Manufacturers Epstein Becker & Green, P.C.
Aug
31
2016
FDA Announces November Public Hearing on Off-Label Communications: An Important Step Forward or a Signal that FDA is Headed Back to the Drawing Board? Epstein Becker & Green, P.C.
Jul
28
2020
FDA Issues Draft Guidance on Cannabis Clinical Research and Sends CBD Enforcement Discretion Guidance to OMB for Review Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins